Russian government aims to increase drug exports in coming years

19 December 2017

The Russian government plans to create conditions to increase exports of domestic drugs, which will be effected through the provision of support, both direct and indirect, to local drugmakers and other benefits, including tax and customs, reports The Pharma Letter’s local correspondent.

Since 2012, exports of Russian drugs have increased more than threefold, however they still remain low, which has sparked concerns for the Russian government.

For the first nine months of 2017 Russian drug exports out grew by 17% on year-on-year basis to $350.7 million in value terms, a figure significantly lower than initially predicted by the state.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK